SG11201408228QA - Dual receptor antagonistic antigen-binding proteins and uses thereof - Google Patents

Dual receptor antagonistic antigen-binding proteins and uses thereof

Info

Publication number
SG11201408228QA
SG11201408228QA SG11201408228QA SG11201408228QA SG11201408228QA SG 11201408228Q A SG11201408228Q A SG 11201408228QA SG 11201408228Q A SG11201408228Q A SG 11201408228QA SG 11201408228Q A SG11201408228Q A SG 11201408228QA SG 11201408228Q A SG11201408228Q A SG 11201408228QA
Authority
SG
Singapore
Prior art keywords
amgen
lllll
international
center drive
dual receptor
Prior art date
Application number
SG11201408228QA
Inventor
Huiquan Han
Xiaolan Zhou
Qing Chen
Mei-Mei Tsai
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11201408228QA publication Critical patent/SG11201408228QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/188448 A3 (51) International Patent Classification: C12P 21/08 (2006.01) C07H 21/04 (2006.01) C07K16/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/045245 11 June 2013 (11.06.2013) English (30) Priority Data: 61/658,237 11 June 2012 (11.06.2012) English US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). (72) Inventors: HAN, Huiquan; C/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). ZHOU, Xiaolan; C/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). CHEN, Qing; C/o Amgen Inc., One Amgen Center Drive, Thou­ sand Oaks, CA 91320-1799 (US). TSAI, Mei-Mei; C/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). (74) Agents: HUBL, Susan et al.; Fenwick & West LLP, 801 California Street, Mountain View, CA 94041 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) [Continued on next page] (54) Title: DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF FIG 4 A 00 00 00 28n 24- * 20- 16- •12- £ 8- I 1 2 3 Time (week) 1x/wk, SC, 4 wks n=8 per group *: p<0.05 P<0.01 ***: p<0.QQ1 24% 1 17% 1 3 rrsg/Ky iUrog/KQ 30mg/kg 23% T 27% t T-H o CJ O (57) Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody ActRII to receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth. WO 2013/188448 A3 I lllll llllllll II llllll III lllll lllll III III III lllll lllll lllll llll lllll lllll lllllll llll llll llll (88) Date of publication of the international search report: 10 April 2014
SG11201408228QA 2012-06-11 2013-06-11 Dual receptor antagonistic antigen-binding proteins and uses thereof SG11201408228QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261658237P 2012-06-11 2012-06-11
PCT/US2013/045245 WO2013188448A2 (en) 2012-06-11 2013-06-11 Dual receptor antagonistic antigen-binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
SG11201408228QA true SG11201408228QA (en) 2015-01-29

Family

ID=49758865

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201610356YA SG10201610356YA (en) 2012-06-11 2013-06-11 Dual receptor antagonistic antigen-binding proteins and uses thereof
SG11201408228QA SG11201408228QA (en) 2012-06-11 2013-06-11 Dual receptor antagonistic antigen-binding proteins and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201610356YA SG10201610356YA (en) 2012-06-11 2013-06-11 Dual receptor antagonistic antigen-binding proteins and uses thereof

Country Status (21)

Country Link
US (4) US9453080B2 (en)
EP (3) EP3498857A1 (en)
JP (1) JP2015525230A (en)
KR (1) KR20150030706A (en)
CN (1) CN104540961A (en)
AU (1) AU2013274347B2 (en)
BR (1) BR112014031028A2 (en)
CA (1) CA2877669A1 (en)
CL (1) CL2014003372A1 (en)
CO (1) CO7240399A2 (en)
EA (1) EA201492282A1 (en)
HK (1) HK1208499A1 (en)
IL (1) IL236133A0 (en)
MA (1) MA37761A1 (en)
MX (1) MX2014015195A (en)
NZ (1) NZ703724A (en)
PE (1) PE20150642A1 (en)
PH (1) PH12014502754A1 (en)
SG (2) SG10201610356YA (en)
TN (2) TN2015000448A1 (en)
WO (1) WO2013188448A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188448A2 (en) 2012-06-11 2013-12-19 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
CN108409856B (en) 2012-09-13 2022-03-04 百时美施贵宝公司 Fibronectin based scaffold domain proteins that bind to myostatin
WO2016092439A1 (en) * 2014-12-08 2016-06-16 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
GB201500464D0 (en) * 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
CN109311998A (en) * 2016-02-22 2019-02-05 阿塞勒隆制药公司 For increasing immunocompetent ActRII antagonist
US10307455B2 (en) 2016-03-10 2019-06-04 Acceleron Pharma Inc. Activin type 2 receptor antibodies
AU2017357944A1 (en) 2016-11-10 2019-06-20 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
JOP20190152A1 (en) * 2016-12-21 2019-06-20 Novartis Ag Myostatin, activin or activin receptor antagonists for use in treating obesity and related conditions
US11693013B2 (en) * 2017-03-10 2023-07-04 UCL Business Ltd. Method relating to myostatin pathway inhibition
US11104737B2 (en) 2017-03-28 2021-08-31 Rigel Pharmaceuticals, Inc. ACVR2A-specific antibody and method of treatment of muscle atrophy
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN112292144A (en) 2018-01-12 2021-01-29 科乐斯疗法公司 Activin receptor type IIB variants and methods of use thereof
CN114127087A (en) * 2019-05-30 2022-03-01 艾科赛扬制药股份有限公司 ACTRII binding proteins and uses thereof
EP4121088A1 (en) * 2020-03-20 2023-01-25 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
FR2664073A1 (en) 1990-06-29 1992-01-03 Thomson Csf MEANS FOR MARKING OBJECTS, METHOD FOR PRODUCING THE SAME, AND DEVICE FOR READING.
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
JPH07503132A (en) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド Transgenic non-human animals capable of producing xenoantibodies
CA2135313A1 (en) 1992-06-18 1994-01-06 Theodore Choi Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1278778A2 (en) 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
CA2891010C (en) * 2004-07-23 2022-09-20 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
WO2008016356A2 (en) * 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
TWI454479B (en) 2007-03-06 2014-10-01 Amgen Inc Variant activin receptor polypeptides and uses thereof
PE20150680A1 (en) 2008-11-26 2015-05-16 Amgen Inc VARIANTS OF ACTIVIN IIB RECEPTOR POLYPEPTIDES AND APPLICATIONS OF THEM
HUE035240T2 (en) * 2009-04-27 2018-05-02 Novartis Ag Compositions and methods for increasing muscle growth
US8524217B2 (en) * 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
CA2859504A1 (en) 2011-12-19 2013-07-18 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
WO2013188448A2 (en) * 2012-06-11 2013-12-19 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
JP6071725B2 (en) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 Driving force control device for electric vehicles

Also Published As

Publication number Publication date
PE20150642A1 (en) 2015-05-26
TN2014000513A1 (en) 2016-03-30
EP2859114B1 (en) 2019-05-15
JP2015525230A (en) 2015-09-03
EP2859114A4 (en) 2016-08-03
IL236133A0 (en) 2015-01-29
WO2013188448A2 (en) 2013-12-19
HK1208499A1 (en) 2016-03-04
US20150152194A1 (en) 2015-06-04
AU2013274347A1 (en) 2015-02-05
WO2013188448A8 (en) 2014-05-08
US20170107288A1 (en) 2017-04-20
CA2877669A1 (en) 2013-12-19
CO7240399A2 (en) 2015-04-17
NZ703724A (en) 2017-06-30
AU2013274347B2 (en) 2018-03-08
TN2015000448A1 (en) 2017-04-06
CL2014003372A1 (en) 2015-04-10
MA37761A1 (en) 2017-09-29
BR112014031028A2 (en) 2017-08-15
EP3540070A1 (en) 2019-09-18
CN104540961A (en) 2015-04-22
US20210340262A1 (en) 2021-11-04
EP2859114A2 (en) 2015-04-15
MX2014015195A (en) 2015-02-17
PH12014502754A1 (en) 2015-03-02
EA201492282A1 (en) 2015-07-30
US9453080B2 (en) 2016-09-27
US10266598B2 (en) 2019-04-23
KR20150030706A (en) 2015-03-20
EP3498857A1 (en) 2019-06-19
SG10201610356YA (en) 2017-01-27
US10981999B2 (en) 2021-04-20
WO2013188448A3 (en) 2014-04-10
US20190256605A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
SG11201408228QA (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201908391XA (en) Methods for modulating an immune response
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201805784PA (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201807474SA (en) Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins